Categoria
Daypro
Nombres de marca,
Daypro
Analogos
Daypro
Marca los nombres de mezcla
No information avaliable
Daypro
Formula quimica
C18H15NO3
Daypro
RX enlace
http://www.rxlist.com/cgi/generic/oxaproz.htm
Daypro
FDA hoja
Daypro
MSDS (hoja de seguridad de materiales)
Daypro
Sintesis de referencia
No hay información disponible
Daypro
Peso molecular
293.317 g/mol
Daypro
Punto de fusion
158 - 159 oC
Daypro
H2O Solubilidad
Insoluble
Daypro
Estado
Solid
Daypro
LogP
4.8
Daypro
Formas de dosificacion
Tableta
Daypro
Indicacion
Se utiliza para aliviar la inflamación, hinchazón, rigidez y dolor en las articulaciones asociados con la artritis reumatoide y la osteoartritis.
Daypro
Farmacologia
Oxaprozina es un fármaco antiinflamatorio no esteroideo (AINE) con propiedades analgésicas y antipiréticas. Oxaprozina se utiliza para tratar la artritis reumatoide, osteoartritis, dismenorrea, y para aliviar el dolor moderado.
Daypro
Absorcion
Oxaprozina es del 95% absorbe por vía oral. Los alimentos pueden reducir la tasa de absorción de oxaprozina, pero el grado de absorción no se modifica. Los antiácidos no afectan significativamente el alcance y la velocidad de absorción de oxaprozina.
Daypro
Toxicidad
Ratón por vía oral, LD50 = 1210 mg / kg, conejo Oral: LD50 = 172 mg / kg; Oral, rata: DL50 = 4470 mg / kg
Daypro
Informacion de Pacientes
Daypro, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as
gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious
gastrointestinal tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the
signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign
or symptoms. Patients should be apprised of the importance of this follow-up.
Patients should report to their physicians the signs or symptoms of gastrointestinal ulceration or bleeding, skin
rash, weight gain, or edema.
Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy,
pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, patients
should be instructed to stop therapy and seek immediate medical therapy.
Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.
In late pregnancy, as with other NSAIDs, Daypro should be avoided because it will cause premature closure of the
ductus arteriosus.
Daypro
Organismos afectados
Humanos y otros mamíferos